Azacitidine — CPB 0960 | AETNA Coverage Update

Aetna modified CPB 0960 for azacitidine (Vidaza), effective September 26, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its azacitidine coverage policy under CPB 0960 to expand the list of covered indications. The revision adds Peripheral T-cell Lymphoma (PTCL) as a covered indication with specific criteria, and clarifies coverage for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in combination with venetoclax. If your team bills J9025 for azacitidine injections — or pairs it with administration codes like 96401, 96413, or 96415 — this update changes what you can get paid for and what documentation you need.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Azacitidine (CPB 0960)
Policy Code	CPB 0960
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Hematology/Oncology, Infusion Therapy, Hospital Outpatient, Inpatient
Key Action	Update prior authorization requests and ICD-10 mappings to include new covered indications before billing claims after September 26, 2025

---

Aetna Azacitidine Coverage Criteria and Medical Necessity Requirements 2025

The Aetna azacitidine coverage policy under CPB 0960 defines medical necessity across six distinct indications. Get the criteria right before you submit — azacitidine is expensive, and a missing diagnosis code or wrong indication triggers a claim denial fast.

Myelodysplastic Syndromes (MDS) is the foundational covered indication. Aetna covers azacitidine for MDS broadly, including all subtypes captured under ICD-10 codes D46.0 through D46.9. This is the most common billing scenario for J9025.

Acute Myeloid Leukemia (AML) is also covered. Map to C92.0, C92.1, C92.2, C92.60–C92.62, or C92.A0–C92.A2 depending on the specific AML subtype. Get the ICD-10 right at the encounter level — vague coding here is a common denial trigger.

Accelerated phase or blast phase myeloproliferative neoplasm maps to D75.81. Make sure your oncologist's documentation specifically identifies the phase. "Myelofibrosis" without phase documentation won't hold up on appeal.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is covered under CPB 0960, but only in combination with venetoclax — and only in one of two settings: relapsed or refractory disease, or systemic disease treated with palliative intent. The combination requirement is non-negotiable. If your claim shows azacitidine alone for BPDCN, expect a denial. Confirm the treatment regimen is documented in the record before you bill. ICD-10 codes C86.40 and C86.41 apply here.

MDS/MPN Overlap Neoplasms are covered as a group. This includes Chronic Myelomonocytic Leukemia (CMML), Juvenile Myelomonocytic Leukemia (JMML), BCR-ABL negative atypical chronic myeloid leukemia (aCML), MDS/MPN with neutrophilia, unclassifiable MDS/MPN, MDS/MPN NOS, MDS/MPN with ring sideroblasts and thrombocytosis, and MDS/MPN with SF3B1 mutation. Use C93.10–C93.12 for CMML, C93.30–C93.32 for JMML, C92.20–C92.22 for aCML, and D47.1 for unclassifiable MPN overlap.

Peripheral T-cell Lymphoma (PTCL) is the newly added indication in this revision. This is the most important change in the September 26, 2025 update. Aetna now covers azacitidine for PTCL — specifically including angioimmunoblastic T-cell lymphoma (AITL), nodal PTCL with TFH phenotype, and follicular T-cell lymphoma (FTCL) — but with tight restrictions. Both of the following criteria must be met:

#	Covered Indication Copy
1	Azacitidine is used as subsequent therapy for relapsed or refractory disease — not first-line.
2	Azacitidine is used as a single agent — not in combination with other drugs.

Miss either condition and you're looking at a denial. If your oncologist is using azacitidine for PTCL in combination with anything else, this coverage policy does not apply.

Prior authorization requirements are not explicitly detailed in the CPB text, but azacitidine is a high-cost injectable chemotherapy agent. Aetna routinely requires prior auth for oncology drugs at this price point. Confirm prior authorization requirements with Aetna directly for each indication before scheduling treatment.

Continuation of therapy is covered when the member has an approved indication and shows no unacceptable toxicity or disease progression. Document clinical response at each cycle to support continued reimbursement.

---

Aetna Azacitidine Exclusions and Non-Covered Indications

Aetna is direct: any indication not listed in Section I of CPB 0960 is considered experimental, investigational, or unproven. There's no gray area here.

The practical implication is that off-label uses — even ones supported by emerging clinical literature — won't qualify for coverage under this policy. If your team is billing azacitidine for a diagnosis that doesn't map to one of the six covered indications, you need to either pursue a medical exception or stop billing Aetna for it.

PTCL as a first-line treatment is also excluded. The policy restricts PTCL coverage to relapsed or refractory disease only. If a patient is treatment-naive, azacitidine for PTCL is not covered — even with a correct PTCL diagnosis code.

BPDCN treated with azacitidine as a single agent (without venetoclax) does not meet medical necessity under this policy. Document the combination therapy clearly in the treatment record.

---

Coverage Indications at a Glance

---

Aetna Azacitidine Billing Guidelines and Action Items 2025

The effective date for this policy update is September 26, 2025. Claims for dates of service on or after that date are subject to the revised CPB 0960 criteria.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Azacitidine Under CPB 0960

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J9025	HCPCS	Injection, azacitidine, 1 mg

This is the primary billing code for azacitidine reimbursement. Units reflect the total milligrams administered. Make sure your J9025 units match the documented dose — under-billing and over-billing both create audit exposure.

Administration CPT Codes (Related to the CPB)

These codes bill alongside J9025 for the chemotherapy administration service itself. The correct code depends on the route and duration.

Subcutaneous azacitidine bills with 96401. Intravenous azacitidine bills with 96413 as the primary code, plus 96414 or 96415 for additional hours. Use 96416 and 96417 for prolonged or sequential infusion scenarios.

Key ICD-10-CM Diagnosis Codes

---